Skip to main content
REPL logo

Replimune Group, Inc.

REPLNASDAQHealthcareBiotechnology

$11.46Today:- (-)1Y +42.40%

As of Oct 23, 2026 close

Market cap
$1.11B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.50$16.33
Volume (live)
-
Avg. volume (3M)
1.97M

Replimune Group (REPL) Cash Flow Statement

In fiscal 2026 (fiscal year ended Mar 31, 2026), Replimune Group used $280.34M of cash in operating activities and spent $4.22M on capital expenditures. That left free cash flow of −$284.57M.

Replimune Group Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Replimune Group, Inc. (REPL) - Annual data in millions USD
BreakdownFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Operating Activities
Net Income-313.94-247.30-215.79-174.28-118.04-80.87-52.63-30.83-19.70-7.70
Depreciation & Amortization6.533.502.662.452.151.710.530.150.110.12
Deferred Income Tax0.000.000.000.040.000.00-0.953.740.850.00
Stock Based Compensation32.2735.0434.1328.1324.2511.797.742.730.810.21
Change in Working Capital-3.8420.972.4415.124.713.51-15.41-1.251.890.15
Change in Accounts Receivable0.451.30-1.92-0.06-0.250.33-0.63-0.26-0.77-1.21
Change in Inventory0.000.000.000.060.250.000.630.260.000.00
Change in Accounts Payable-4.949.94-2.791.981.12-1.03-3.820.121.600.20
Change in Other Working Capital-1.094.684.2013.142.531.13-11.59-1.370.30-0.06
Other Operating Activities-1.374.684.200.492.532.470.160.090.030.15
Net Cash from Operating Activities-280.34-192.25-185.47-128.05-82.18-61.39-60.55-25.38-16.01-7.08
Investing Activities
Capital Expenditures-4.22-6.69-5.66-2.27-2.34-2.39-6.54-2.60-0.14-0.24
Acquisitions0.000.000.000.140.000.000.000.000.000.00
Purchases of Investments-77.89-403.59-489.52-583.41-255.72-392.43-149.68-189.93-52.460.00
Sales/Maturities of Investments392.96386.48592.38443.18256.25206.05150.99126.598.550.00
Other Investing Activities0.000.000.00-0.140.000.000.00-63.34-43.910.00
Net Cash from Investing Activities310.84-23.8097.20-142.50-1.81-188.78-5.23-65.94-44.05-0.24
Financing Activities
Debt Repayment34.26-0.60-0.4827.79-0.26-10.009.940.000.000.00
Common Stock Issued32.03155.731.76187.296.86383.5061.88103.3454.7515.00
Other Financing Activities-0.7497.00-0.4896.220.00-1.0428.34-1.9554.7515.00
Net Cash from Financing Activities66.29252.4016.28311.306.60372.46100.17101.3954.7515.00
Summary
Effect of Forex Changes on Cash1.110.32-0.09-0.110.820.72-0.14-0.842.30-1.42
Net Change in Cash97.9136.67-72.0740.64-76.57123.0234.259.23-3.016.27
Cash at Beginning of Period112.8276.16148.23107.58184.1561.1426.8917.6620.6714.41
Cash at End of Period210.73112.8276.16148.23107.58184.1561.1426.8917.6620.67
Free Cash Flow-284.57-198.94-191.13-130.32-84.52-63.78-67.09-27.98-16.15-7.32
Supplemental Disclosures
Interest Paid-4.203.041.07-0.64----
Income Taxes Paid-0.110.30-0.06-----

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Replimune Group Cash Flow

What is Replimune Group's free cash flow?

Replimune Group had negative free cash flow of $284.57M in fiscal 2026 (fiscal year ended Mar 31, 2026), operating cash flow of −$280.34M minus $4.22M of capital expenditures.

How much does Replimune Group spend on capital expenditures?

Replimune Group spent $4.22M on capital expenditures in fiscal 2026, compared with $6.69M a year earlier.

Does Replimune Group pay dividends or buy back shares?

Replimune Group's cash flow statement for fiscal 2026 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition